<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion/References</th>
<th>Institution Vote</th>
</tr>
</thead>
</table>
| **PANC-1**  
External Request  
Submission from Foundation Medicine, Inc., to consider adding “comprehensive genomic profiling” to the initial workup of a patient with locally advanced or metastatic pancreatic cancer. | Based on the data in the noted references and discussion, the panel consensus was to include “consider somatic testing as clinically indicated” as an option for patients with metastatic pancreatic cancer, along with the following footnote: “Consider somatic testing for patients who are candidates for anti-cancer therapy,” This is a category 2A recommendation.  
See Submission for references. | YES 0  ABSTAIN 9 |
| **PANC-F**  
Internal Request:  
Institutional review comment to consider including modified FOLFIRINOX as an option everywhere FOLFIRINOX is recommended. | Based on the data in the noted reference and discussion, the panel consensus was to include modified FOLFIRINOX as an option in the following settings for patients with good performance status, ECOG 0-1:  
- Preferred regimen option for neoadjuvant therapy, adjuvant therapy (category 1), and first-line therapy for locally advanced/metastatic disease.  
- For patients with known BRCA1/2 or PALB2 mutations, preferred regimen option for neoadjuvant therapy, and first-line therapy for locally advanced/metastatic disease.  
- Other recommended regimen option for second-line therapy for locally advanced/metastatic disease, and recurrence therapy.  
| **PANC-F**  
Internal Request  
Institutional review comment to consider adding “PALB2” mutations to the indications for gemcitabine + cisplatin where included as an option. | Based on the data in the noted reference and discussion, the panel consensus was to include PALB2 mutations as an indication for gemcitabine + cisplatin in the following settings:  
- Neoadjuvant therapy  
- First-line therapy for locally advanced/metastatic disease  
- Second-line therapy for locally advanced/metastatic disease  
- Therapy for recurrent disease  